Citius Pharmaceuticals Inc
For the period ended Mar 12, 2024. Filed Jan 26, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Mar 12, 2024 · Filed Jan 26, 2024
Contents
General Compensation Process
The Compensation Committee is responsible for determining the elements and levels of compensation for our Named Executive Officers. In doing so, the Compensation Committee reviews our corporate performance against financial and corporate achievement measures, assesses individual performance and evaluates recommendations of the Chief Executive Officer regarding compensation for other Named Executive Officers. Deliberations of the Compensation Committee may occur within a meeting of the full Board of Directors at which all members of the Compensation Committee are in attendance and the Board of Directors may take action in such meetings upon the advice of the Compensation Committee Chair and/or its members.
To assist in its deliberations regarding executive compensation, in fiscal 2018 and again in fiscal 2021 the Compensation Committee directly engaged FW Cook as its compensation consultant. FW Cook does not undertake any work for us other than its services for the Compensation Committee. The Compensation Committee has determined that FW Cook is independent and that its services do not raise any conflict of interest with us or any of our executive officers or directors. In carrying out its work for the Compensation Committee, FW Cook interacts from time to time directly with our management, as it determines appropriate, regarding its work product prior to presentation to the Compensation Committee in order to confirm alignment with our business strategy and obtain data or information necessary for its work.
FW Cook reviewed and discussed with the Compensation Committee competitive market compensation data for consideration when determining different levels and mix of compensation. The Compensation Committee reviewed publicly available compensation information of executive officers as well as aggregate share usage and dilution of a peer group of companies within the biotechnology and pharmaceuticals industries. These companies were selected by the Compensation Committee with FW Cook’s assistance and were similar to the Company in terms of size, business model and state of development.
The peer group consisted of the following companies:
| ● | Arbutus Biopharma Corporation | ● | Matinas BioPharma Holdings, Inc. |
| ● | Cidara Therapeutics, Inc. | ● | Novan, Inc. |
| ● | ContraFect Corporation | ● | OpGen, Inc. |
| ● | CorMedix Inc. | ● | Oragenics, Inc. |
| ● | Cue Biopharma, Inc. | ● | Regulus Therapeutics Inc. |
| ● | Genocea Biosciences, Inc. | ● | SCYNEXIS, Inc. |
| ● | Heat Biologics, Inc. | ● | Spero Therapeutics, Inc. |
| ● | Hepion Pharmaceuticals, Inc. | ● | XBiotech Inc. |
| ● | HOOKIPA Pharma Inc. | ||
The peer company compensation data provided by FW Cook is used by the Compensation Committee as a general reference point in its compensation review. The Compensation Committee does not set compensation levels at any specific level or percentile against this compensation data (i.e., the Compensation Committee does not “benchmark” our executive compensation levels). The peer group data is only one point of information taken into account by the Compensation Committee in making compensation decisions.
After review and approval by the Compensation Committee of FW Cook’s recommendations, in August 2021, the Board adopted the Committee’s recommendation for stock option grant guidelines as well as increases in executive compensation.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.